Milestone Pharmaceuticals Inc. – Filings and Transcripts

NASDAQ: MIST
Share price (3/26/26): $1.15
Market cap (3/26/26): $135 million

Warning: Large portions of this site require JavaScript enabled in order to function properly. Please make sure JavaScript is enabled in your browser.

Please let us know at support@bamsec.com if you have any questions or concerns.

Search in Documents

Key Exhibits

External Links

Financials Filter

ended 12/31/25 FY 2025

ended 09/30/25 Q3

ended 06/30/25 Q2

ended 03/31/25 Q1

ended 12/31/24 FY 2024

Prospectuses and Registrations Filter

Registration of securities for employees

Prospectus supplement for primary offering

Prospectus supplement for primary offering

Prospectus supplement for primary offering

Registration of securities for employees

Ownership Filter

Trails Edge Capital Partners, LP

Sandoval David I.

Nelson Jeffrey Edward

News Filter

Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Update on the Commercial Launch of CARDAMYST™ (Etripamil) Nasal Spray for the Treatment of PSVT

Announces U.S. Availability of CARDAMYST™ (Etripamil) Nasal Spray, the First and Only FDA-Approved Self-Administered Treatment for Adults With Paroxysmal Supraventricular Tachycardia

Announces Acceptance of Marketing Authorization Application for Etripamil Nasal Spray in PSVT by the European Medicines Agency

Receives FDA Approval of CARDAMYST™ (Etripamil) as First and Only Self-Administered Nasal Spray for Adults With Paroxysmal Supraventricular Tachycardia

Proxies Filter

Additional info about upcoming vote

Definitive proxy

Additional info about upcoming vote

Additional info about upcoming vote

Definitive proxy

Other Filter

Scanned paper annual report submission

Notice of effectiveness

Correspondence with the SEC

Letter from the SEC

Scanned paper annual report submission